Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist. Activation of MR on cells in the distal nephron, podocytes, fibroblasts, vascular cells, and macrophages plays a key role in driving inflammation, tubular injury, and fibrosis progression in the kidneys of patients with diabetic nephropathy (DN). Finerenone has demonstrated the ability to slow the decline in kidney function and reduce the incidence of kidney failure or kidney disease-related death. It is also associated with a reduced risk of adverse cardiovascular outcomes. However, there is limited data on the use of finerenone in the Indian population. Therefore, we conducted this retrospective study to evaluate the impact of finerenone on kidney function in patients with diabetic nephropathy in the Indian clinical setting.
We retrospectively analyzed data from patients with diabetic nephropathy due to type 2 diabetes who received finerenone, had serum potassium levels below 4.8 mEq/L, and an eGFR above 25 ml/min/1.73 m². Patient demographics, urine albumin-creatinine ratio (UACR), serum creatinine (SCr), and serum potassium levels were recorded both at baseline and at the latest follow-up. Data were analyzed using descriptive statistics along with appropriate statistical tests. The study was approved by the institutional ethics committee.
Between August 2022 and September 2025, a total of 65 DN patients had received Finerenone. The median age was 61 years (range: 24 to 82 years) and 55(84.62%) were males. The median body mass index was 26.84 Kg/m2 and blood pressure was 140/80 mmHg. The median HbA1c level at baseline was 7.90%. At baseline, all the patients were on stable dose angiotensin receptor blockers and dapagliflozin. After a median follow-up of 1122 days, the SCr (baseline: 2.02 mg/dL to 2.90 mg/dL at latest follow-up) and serum potassium (baseline:4.50 mEq/L to 4.76 mEq/L at latest follow-up) had remained stable. The median urinary albumin-to-creatinine ratio (UACR) significantly decreased from 1539 mg/g at baseline to 1042 mg/g at follow-up, indicating a substantial reduction in proteinuria. No significant adverse events were identified in any of the patients. Four(6.15%) patients had developed hyperkalemia ( ≥5.5mEq/L).
In this prospective observational study, finerenone demonstrated a favourable safety profile and variable efficacy in reducing albuminuria among patients with diabetic kidney disease already receiving maximum tolerated doses of dapagliflozin and telmisartan.A gradient effect was observed, with patients exhibiting higher baseline UACR achieving greater reductions in proteinuria. These findings reinforce the role of finerenone as an anti-albuminuric agent in diabetic nephropathy management and support its integration into multidrug strategies aimed at slowing disease progression. However, the observed heterogeneity in response highlights the need for personalized therapeutic approaches and biomarker-based patient selection. Larger, controlled studies are warranted to validate these results and optimize the clinical use of finerenone in diverse diabetic kidney disease population patients.
